SyntekaBio

SyntekaBio FCF Growth

The Year-over-Year Free Cash Flow Growth of SyntekaBio (226330.KQ) as of Nov 20, 2026 is 34.26 %. In the previous year, Year-over-Year Free Cash Flow Growth was 6.75 % — a change of 407.31% (higher).

FCF Growth

34.26 %

YoY

407.31%

Last updated:

Year-over-Year Free Cash Flow Growth of SyntekaBio is 2025 34.26 % . Year-over-Year Free Cash Flow Growth of SyntekaBio was 2024 6.75 % . It decreases by 407.31% higher compared to the previous year.

The SyntekaBio FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2018
-18.06 KRW
Jan 1, 2019
-36.60 KRW
Jan 1, 2020
-32.41 KRW
Jan 1, 2021
-147.75 KRW
Jan 1, 2022
-27.72 KRW
Jan 1, 2023
-1.39 KRW
Jan 1, 2024
6.75 KRW
Jan 1, 2025
34.26 KRW
The SyntekaBio FCF Growth history
YEARFCF GrowthYoY
34.26 %+407.31%
6.75 %-585.54%
-1.39 %-94.98%
-27.72 %-81.24%
-147.75 %+355.92%
-32.41 %-11.46%
-36.60 %+102.69%
-18.06 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SyntekaBio Stock analysis

What does SyntekaBio do? SyntekaBio Inc. provides bioinformatics solutions through AI-driven software and services. The company develops and sells PMAP, a personal algorithm dielectric map platform using artificial intelligence, and offers clinical trial modeling and genome analysis services via big data. These services diagnose genetic diseases, select biomarker treatments, and predict disease risk. SyntekaBio also develops AI drug development technology and provides research services for candidate substances of immuno-cancer drugs. The primary customers for SyntekaBio's products include healthcare providers, research institutions, and pharmaceutical companies. Healthcare providers use the diagnostic and predictive services for patient care, while research institutions and pharmaceutical firms utilize the genome analysis and drug development technologies. The company's AI-driven tools are tailored to meet the needs of these segments, focusing on precision medicine and oncology applications. SyntekaBio's revenue streams come from software sales, service contracts for clinical trial modeling and genome analysis, and research services for immuno-cancer drug candidates. The company's AI drug development technology is a key offering, targeting pharmaceutical companies seeking to accelerate drug discovery and development processes. The firm's focus on AI and big data analytics positions it as a provider of specialized solutions in the bioinformatics sector. SyntekaBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SyntekaBio stock

Year-over-Year Free Cash Flow Growth of SyntekaBio is 34.26 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth SyntekaBio since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's SyntekaBio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — SyntekaBio

All Key Metrics — SyntekaBio